Novartis' Asciminib, which is attracting attention as a fourth-generation targeted anticancer drug in the chronic leukemia treatment market, is also speeding up domestic permits.

The drug, which was approved by the U.S. FDA last month, has recently been approved for four clinical plans in Korea alone, boosting the analysis that it is accelerating its entry into the Korean market. According to the MFDS on the 26th, Asciminib has been approved for four clinical plans since August. Asciminib is a TKI (tyrosine kinase inhibitor) family fourth-generation targeted anticancer, and is attracting attention in that it attacks targets different from those of the first to third generations. This is because differe